EHA 2021 – allo hints for Celyad while Autolus chases CD19

Snippets

Two years after spelling out its off-the-shelf Car-T ambitions Celyad has some early human data to go on. A presentation at the upcoming European Hematology Association meeting is set to detail the first multiple myeloma patients given CYAD-211, an allogeneic anti-BCMA construct that uses shRNA to silence endogenous T-cell receptors without gene editing. An abstract released this week shows one partial remission among two fifth-line subjects, with – importantly – no graft-versus-host disease in either. At the June 11 EHA session analysts hope to see data on further patients, perhaps at a higher cell dose. Another cell therapy player, Autolus, spiked this week on continued promise from its Car-T asset, Auto1, with its EHA abstract showing 100% complete remission in indolent lymphoma, and a remarkably low rate of neurotoxicity and cytokine release. Still, this is one of a multitude of projects targeting CD19. Investors are also keenly awaiting data at EHA from Forma’s FT-4202, a mechanistic rival to Agios’s mitapivat that impressed at Ash, though for now the biggest beneficiary of EHA appears to have been Curis.

Selected early clinical data being presented at the European Hematology Association conference
Project Company Disease (trial) Data Abstract
CYAD-211 Celyad 4L multiple myeloma (Immunicity-1/ NCT04613557)  1/2 PR rate; no GvHD EP739
Auto1 Autolus r/r indolent B-cell lymphomas (NCT02935257) 9/9 CR rate; no CRS above gr2; no ICANS EP788
FT-4202 Forma Sickle cell disease (NCT03815695) Data from 600mg & 12wk open-label 400mg doses to be presented EP1202
BGB-11417 Beigene Non-Hodgkin's lymphoma (NCT04277637) Novel Bcl2 inhibitor; safety data only in abstract EP525
Source: EHA abstracts.

The virtual EHA conference will take place June 9-12.

Related Topics

Share This Article